CN104582732A - 治疗癌症的组合物及其制造方法 - Google Patents
治疗癌症的组合物及其制造方法 Download PDFInfo
- Publication number
- CN104582732A CN104582732A CN201380043472.9A CN201380043472A CN104582732A CN 104582732 A CN104582732 A CN 104582732A CN 201380043472 A CN201380043472 A CN 201380043472A CN 104582732 A CN104582732 A CN 104582732A
- Authority
- CN
- China
- Prior art keywords
- cancer
- conjugate
- lipid
- compositionss
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261689950P | 2012-06-15 | 2012-06-15 | |
| US61/689,950 | 2012-06-15 | ||
| US201261797484P | 2012-12-07 | 2012-12-07 | |
| US61/797,484 | 2012-12-07 | ||
| PCT/US2013/045893 WO2013188763A1 (en) | 2012-06-15 | 2013-06-14 | Compositions for treating cancer and methods for making the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104582732A true CN104582732A (zh) | 2015-04-29 |
Family
ID=49758748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380043472.9A Pending CN104582732A (zh) | 2012-06-15 | 2013-06-14 | 治疗癌症的组合物及其制造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9789193B2 (und) |
| EP (1) | EP2861256B1 (und) |
| JP (2) | JP6427097B2 (und) |
| CN (1) | CN104582732A (und) |
| AU (2) | AU2013274101B2 (und) |
| BR (1) | BR112014031421A2 (und) |
| WO (1) | WO2013188763A1 (und) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105044343A (zh) * | 2015-08-14 | 2015-11-11 | 山东省肿瘤防治研究院 | 一种食管鳞状细胞癌诊断模型的构建方法、所得诊断模型及模型的使用方法 |
| CN109071527A (zh) * | 2016-02-11 | 2018-12-21 | 成事在人肿瘤学公司 | 细胞信号传导抑制剂、它们的制剂及其方法 |
| WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101653842B1 (ko) | 2008-01-04 | 2016-09-02 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| CA2824197C (en) | 2011-01-10 | 2020-02-25 | Michael Martin | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| JP6049712B2 (ja) | 2011-07-08 | 2016-12-21 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ | 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子 |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| BR112015031278B1 (pt) | 2013-06-14 | 2022-05-17 | Akamara Therapeutics, Inc | Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer |
| JP6461973B2 (ja) * | 2013-12-20 | 2019-01-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用 |
| CA2929970C (en) | 2013-12-20 | 2020-05-12 | F. Hoffmann-La Roche Ag | Method of immobilizing a cell on a support using compounds comprising a polyethylene glycol moiety |
| CA2930505C (en) | 2013-12-20 | 2019-06-18 | F. Hoffman-La Roche Ag | Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells |
| US10300070B2 (en) | 2014-03-27 | 2019-05-28 | The Brigham And Women's Hospital, Inc. | Metabolically-activated drug conjugates to overcome resistance in cancer therapy |
| CA2944401A1 (en) * | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| JP6731404B2 (ja) | 2014-10-14 | 2020-07-29 | ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 光線力学療法、ｘ線誘起光線力学療法、放射線療法、化学療法、免疫療法、及びこれらの任意の組み合わせのためのナノ粒子 |
| US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
| EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
| EP3265063A4 (en) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| WO2016182988A1 (en) | 2015-05-08 | 2016-11-17 | Memorial Sloan Kettering Cancer Center | Compositions and methods for treatment of glioma |
| EP3416623B1 (en) | 2016-02-15 | 2021-08-11 | University of Georgia Research Foundation, Inc. | Ipa-3-loaded liposomes and methods of use thereof |
| US11246877B2 (en) | 2016-05-20 | 2022-02-15 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
| US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| WO2018146641A1 (en) * | 2017-02-11 | 2018-08-16 | Invictus Oncology Pvt. Ltd. | Novel inhibitors of cellular signalling |
| CN111194232B (zh) | 2017-08-02 | 2023-01-31 | 芝加哥大学 | 纳米级金属有机层和金属有机纳米片 |
| CN111971070A (zh) * | 2017-12-14 | 2020-11-20 | 塔弗达治疗有限公司 | Hsp90-靶向缀合物及其制剂 |
| CN108434457B (zh) * | 2018-04-20 | 2021-06-18 | 长沙创新药物工业技术研究院有限公司 | 一种阿霉素聚乙二醇埃博霉素b偶联物及其制备方法 |
| EA202191228A1 (ru) * | 2018-11-02 | 2021-09-24 | ТЕЗОРКС ФАРМА, ЭлЭлСи | Липосомальная внутрибрюшинная химиотерапия с повышенной степенью эффективности |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| EP4013444A4 (en) * | 2019-08-13 | 2023-11-01 | Peptinovo Biopharma Inc. | PALM FOR THE TREATMENT OF CHEMOTHERAPEUTIC INDUCED PERIPHERAL NEUROPATHY IN THE TREATMENT OF CANCER |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4146274A4 (en) * | 2020-05-04 | 2024-04-17 | Drugcendr Australia Pty Ltd | METHODS OF TREATING PANCREATIC CANCER AND OTHER SOLID TUMORS |
| WO2022125784A1 (en) * | 2020-12-10 | 2022-06-16 | Children's Hospital Medical Center | Enhanced nanoparticle delivery systems |
| JP2024500515A (ja) * | 2020-12-24 | 2024-01-09 | エンハンストバイオ インコーポレイテッド | 脂質ナノ粒子を含む癌の予防または治療用組成物 |
| CN117295747A (zh) | 2021-03-23 | 2023-12-26 | 诺维逊生物股份有限公司 | 抗癌核激素受体靶向化合物 |
| WO2023068958A1 (ru) * | 2021-10-19 | 2023-04-27 | Борис Славинович ФАРБЕР | Супрамолекулярные системы на основе динамических самоорганизующихся наноструктур с противовирусными свойствами |
| CN114288422B (zh) * | 2022-01-21 | 2023-04-28 | 陕西科技大学 | 一种化学靶向降解目标蛋白的脂质体及其制备方法 |
| WO2023230616A2 (en) * | 2022-05-26 | 2023-11-30 | Purdue Research Foundation | Combination of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of use |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209174A1 (en) * | 2001-03-23 | 2005-09-22 | Mcchesney James D | Molecular conjugates for use in treatment of cancer |
| CN1743337A (zh) * | 2004-09-03 | 2006-03-08 | 上海靶点药物有限公司 | 一种紫杉醇衍生物及其药物组合物 |
| US20060079538A1 (en) * | 2004-05-13 | 2006-04-13 | Dennis Hallahan | Methods for inhibiting angiogenesis |
| CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
| CN101878024A (zh) * | 2007-11-28 | 2010-11-03 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| JPH089548B2 (ja) * | 1986-03-14 | 1996-01-31 | 藤沢薬品工業株式会社 | プロドラツグ化合物、その製造法およびそれを含有する持続性製剤 |
| EP0237051B1 (en) | 1986-03-14 | 1991-05-02 | Fujisawa Pharmaceutical Co., Ltd. | Prodrug compounds, process for the preparation thereof and sustained release preparation comprising the same |
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| IL95436A (en) | 1989-08-23 | 1996-07-23 | Centre Nat Rech Scient | Process for preparing the history of phenylisosarine |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5015744A (en) | 1989-11-14 | 1991-05-14 | Florida State University | Method for preparation of taxol using an oxazinone |
| FR2658510B1 (fr) | 1990-02-21 | 1992-04-30 | Rhone Poulenc Sante | Nouveau derive de la beta-phenylisoserine, sa preparation et son emploi. |
| US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| FR2678930B1 (fr) | 1991-07-10 | 1995-01-13 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii. |
| FR2680506B1 (fr) | 1991-08-19 | 1994-09-02 | Rhone Poulenc Rorer Sa | Procede de preparation de derives de la beta-phenylisoserine et leur utilisation. |
| AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| FR2687150B1 (fr) | 1992-02-07 | 1995-04-28 | Rhone Poulenc Rorer Sa | Procede de preparation de derives du taxane. |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| TW225528B (und) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| US5534499A (en) | 1994-05-19 | 1996-07-09 | The University Of British Columbia | Lipophilic drug derivatives for use in liposomes |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JPH11508231A (ja) | 1995-05-26 | 1999-07-21 | ソマティックス セラピー コーポレイション | 安定な脂質／核酸複合体を含む送達ビヒクル |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| TR199800012T1 (xx) | 1995-07-06 | 1998-04-21 | Novartis Ag | Piroloprimidinler ve preparasyon i�in tatbikler. |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| BR9708640B1 (pt) | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| WO1998008849A1 (de) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| CA2264908C (en) | 1996-09-06 | 2006-04-25 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
| CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| EP0941227B2 (de) | 1996-11-18 | 2009-10-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| IL138113A0 (en) | 1998-02-25 | 2001-10-31 | Sloan Kettering Inst Cancer | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| CN1152031C (zh) | 1998-08-11 | 2004-06-02 | 诺瓦提斯公司 | 具有血管生成抑制活性的异喹啉衍生物 |
| US6218367B1 (en) | 1998-09-15 | 2001-04-17 | Organomed Corporation | Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations |
| KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
| GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
| WO2005118612A1 (en) | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
| EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE |
| JP2007099750A (ja) * | 2005-02-25 | 2007-04-19 | Hokkaido Univ | 腫瘍組織で選択的に分解性を示す血中滞留性素子 |
| US9107824B2 (en) * | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| AU2007303205A1 (en) | 2006-10-03 | 2008-04-10 | Tekmira Pharmaceuticals Corporation | Lipid containing formulations |
| DK2481409T3 (en) | 2007-03-07 | 2018-08-06 | Abraxis Bioscience Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US9207990B2 (en) | 2007-09-28 | 2015-12-08 | Hewlett-Packard Development Company, L.P. | Method and system for migrating critical resources within computer systems |
| CA2708153C (en) | 2007-12-04 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| CA2711236A1 (en) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
| WO2010123931A1 (en) * | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
| WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
-
2013
- 2013-06-14 US US14/406,938 patent/US9789193B2/en active Active
- 2013-06-14 CN CN201380043472.9A patent/CN104582732A/zh active Pending
- 2013-06-14 EP EP13805073.7A patent/EP2861256B1/en active Active
- 2013-06-14 WO PCT/US2013/045893 patent/WO2013188763A1/en active Application Filing
- 2013-06-14 JP JP2015517453A patent/JP6427097B2/ja not_active Expired - Fee Related
- 2013-06-14 BR BR112014031421A patent/BR112014031421A2/pt not_active IP Right Cessation
- 2013-06-14 AU AU2013274101A patent/AU2013274101B2/en not_active Ceased
-
2017
- 2017-10-02 US US15/722,831 patent/US10300143B2/en active Active
- 2017-11-24 AU AU2017265136A patent/AU2017265136A1/en not_active Abandoned
-
2018
- 2018-06-21 JP JP2018117597A patent/JP2018188443A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209174A1 (en) * | 2001-03-23 | 2005-09-22 | Mcchesney James D | Molecular conjugates for use in treatment of cancer |
| US20060079538A1 (en) * | 2004-05-13 | 2006-04-13 | Dennis Hallahan | Methods for inhibiting angiogenesis |
| CN1743337A (zh) * | 2004-09-03 | 2006-03-08 | 上海靶点药物有限公司 | 一种紫杉醇衍生物及其药物组合物 |
| CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
| CN101878024A (zh) * | 2007-11-28 | 2010-11-03 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
Non-Patent Citations (1)
| Title |
|---|
| CULLEN M. TANIGUCHI等: "Phosphoinositide 3-kinase regulatory subunit p85 suppresses insulin action via positive regulation of PTEN", 《PNAS》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105044343A (zh) * | 2015-08-14 | 2015-11-11 | 山东省肿瘤防治研究院 | 一种食管鳞状细胞癌诊断模型的构建方法、所得诊断模型及模型的使用方法 |
| CN105044343B (zh) * | 2015-08-14 | 2017-03-08 | 山东省肿瘤防治研究院 | 一种食管鳞状细胞癌诊断模型的构建方法、所得诊断模型及模型的使用方法 |
| CN109071527A (zh) * | 2016-02-11 | 2018-12-21 | 成事在人肿瘤学公司 | 细胞信号传导抑制剂、它们的制剂及其方法 |
| WO2021164789A1 (zh) * | 2020-02-21 | 2021-08-26 | 南京明德新药研发有限公司 | 一种吡唑并嘧啶类化合物的晶型及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2861256A1 (en) | 2015-04-22 |
| US10300143B2 (en) | 2019-05-28 |
| US20150174263A1 (en) | 2015-06-25 |
| JP2015527301A (ja) | 2015-09-17 |
| EP2861256B1 (en) | 2019-10-23 |
| WO2013188763A1 (en) | 2013-12-19 |
| AU2017265136A1 (en) | 2018-01-04 |
| JP2018188443A (ja) | 2018-11-29 |
| AU2013274101B2 (en) | 2017-09-07 |
| JP6427097B2 (ja) | 2018-11-21 |
| EP2861256A4 (en) | 2016-06-01 |
| AU2013274101A1 (en) | 2015-01-29 |
| BR112014031421A2 (pt) | 2017-06-27 |
| US20180125987A1 (en) | 2018-05-10 |
| WO2013188763A9 (en) | 2014-01-23 |
| US9789193B2 (en) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104582732A (zh) | 治疗癌症的组合物及其制造方法 | |
| Xiong et al. | Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer | |
| US10426753B2 (en) | Supramolecular combinatorial therapeutics | |
| Ding et al. | Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer | |
| Zhang et al. | Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models | |
| Lu et al. | Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer | |
| CN105147613A (zh) | 增强药物递送和治疗剂有效性的方法 | |
| CN107921005A (zh) | 利用纳米颗粒治疗肿瘤的组合物和方法 | |
| Liu et al. | Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity | |
| González-Fernández et al. | Antitumoral-lipid-based nanoparticles: a platform for future application in osteosarcoma therapy | |
| Li et al. | Autophagy inhibition recovers deficient ICD-based cancer immunotherapy | |
| Chen et al. | Glutathione-responsive copper-disulfiram nanoparticles for enhanced tumor chemotherapy | |
| Kulkarni et al. | Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy | |
| Gao et al. | A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction | |
| US20160166507A1 (en) | Nanoemulsions of hydrophobic platinum derivatives | |
| Xu et al. | Lipid-coated CaCO3 nanoparticles as a versatile ph-responsive drug delivery platform to enable combined chemotherapy of breast cancer | |
| Zhang et al. | Augment the efficacy of eradicating metastatic lesions and tumor proliferation in breast cancer by honokiol-loaded pH-sensitive targeted lipid nanoparticles | |
| Liang et al. | A NAG-guided nano-delivery system for redox-and pH-triggered intracellularly sequential drug release in cancer cells | |
| WO2018172942A1 (en) | Quercetin nanoparticles | |
| Sang et al. | Lipid-polymer nanocarrier platform enables X-ray induced photodynamic therapy against human colorectal cancer cells | |
| Zhou et al. | Development and investigation of dual potent anticancer drug-loaded nanoparticles for the treatment of lung cancer therapy | |
| WO2016014337A1 (en) | Drug delivery nanoemulsion systems | |
| Chaudhury et al. | Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin | |
| Nagdiya et al. | Drug delivery systems of gefitinib for improved cancer therapy: A review | |
| Huang et al. | A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |